Review (August 2025)
435k
Estimated Revenue
5.32M
Website Visitors
4/5
Trustpilot Score
What do we know about Attentive Therapeutics, Inc.?
What is Attentive Therapeutics, Inc.'s Revenue?
Attentive Therapeutics, Inc.'s estimated revenue for 2024 is $435k.
What does Attentive Therapeutics, Inc. do?
Developing new therapy that combines proven ADHD medications with an appetite stimulant. Recently successfully completed prospective clinical trial demonstrating highly significant impact on weight.
What are the monthly traffic metrics for Clinicaltrials?
6/mo Traffic Growth
-13.00%
All Time Traffic Growth
Create Free Account
Monthly Hits
5M
Time on Site
2.9Mins
Pages per Visit
3.0
Bounce Rate
65%
How fast is Clinicaltrials growing?
Clinicaltrials has grown by 13.2% in the last 6 months according to SimilarWeb.
How do people interact with Clinicaltrials?
Last month, Clinicaltrials received 5M visitors who spent an average of 2.9 minutes on the website and visited 3.0 different pages per session. Overall, 65% of people bounce on the first visit.
How do people find Clinicaltrials?
1.6M people (31%) visit Clinicaltrials directly. 3M (57%) people search for them in Google. Whereas, 89.8k (2%) discover Clinicaltrials through Facebook, Reddit, and YouTube. 32.9k (1%) visitors come from Clinicaltrials's email newsletters. Finally, 992.5 (0.0%) people come from affiliates and or paid referrals.
Who uses Clinicaltrials?
Clinicaltrials's top market is the United States and they receive 2.6M (48.1%) people.Then the 2nd is China with 267.1k (5.0%).The 3rd is is India with 251k (4.7%).
Traffic Growth (last 6 months)
What are Clinicaltrials's ads on Google?
Google Ads
The SUMMIT Clinical Trial - For Advanced Metastatic Cancer
https://www.clinicaltrials.gov/ct2/show/NCT01953926
DAY101 - Phase 1 - Oral pan-RAF Inhibitor
https://clinicaltrials.gov/ct2/show/NCT04775485
Learn about an adult study for an investigational oral pan-RAF inhibitor. Trial for recurrent or progressive tumors expressing RAS/RAF/MEK/ERK pathway alterations. Eligibility Criteria.
DAY101 - Phase 1 - Oral pan-RAF Inhibitor
https://clinicaltrials.gov/ct2/show/NCT04985604
Learn about an adult study for an investigational oral pan-RAF inhibitor. Trial for recurrent or progressive tumors expressing RAS/RAF/MEK/ERK pathway alterations. Currently Enrolling.
The SUMMIT HER2 Cancer Trial - Advanced HER2-Mutated...
https://www.clinicaltrials.gov/ct2/show/NCT01953926
Get more information about this clinical trial for people with HER2-mutated breast cancer. Get more information and find out if you may qualify for the SUMMIT clinical trial today. Stage-4 Patients Only. Urinary Tract Cancer. Metastatic Breast Cancer. EGFR Mutations.
HER2 Mutation Breast Cancer - A Clinical Study of Neratinib
https://www.clinicaltrials.gov/ct2/show/NCT01953926
A clinical study for people with advanced metastatic HER2 mutated breast cancer. Get more information today and find out if you qualify for this clinical research study. EGFR Mutations. Cervical Cancer. Blader Cancer. Study Locations Near You. Salivary Cancer. Lung Cancer.
Keyword: her2 definition
You May Also Find These Company Reviews Interesting